Recent studies suggest that one to two administrations of psilocybin have acute antidepressant effects for people with major depressive disorder. These data on psilocybin have generated considerable enthusiasm, but little empirical attention has been paid to the therapy that adjoins psilocybin treatment (psychedelic-assisted therapy, or PAT).
Materials and Methods:
In this study, we present the initial protocol and plans to empirically test the psychosocial therapy that adjoins psilocybin treatment with the goal of optimizing this therapeutic approach for adults with major depressive disorder. The psychotherapy is based on the principles of cognitive-behavioral therapy (CBT), an evidence-based treatment for major depressive disorder. Participants will be 30 adults with a history of major depressive disorder and current, active depressive symptoms. Following psychiatric and medical safety evaluations, eligible participants will be enrolled in a 12-session CBT that includes classic PAT safety elements (termed psilocybin-assisted CBT; PA-CBT). Following the third and sixth PA-CBT sessions, participants will engage in two psilocybin drug administration sessions (10 and 25 mg, respectively). Participants will provide feedback about the PA-CBT and complete measures of mood symptoms, psychosocial functioning, cognitive schemas, and affective experiences immediately following each drug administration session, at the completion of PA-CBT, and 3 months following treatment completion.
Conclusions:
The trial will provide preliminary data on the feasibility, safety, acceptability, and psychosocial effects of PA-CBT. Results will inform randomized clinical trials to test the effects of PA-CBT for patients with depression and other mental health conditions, as well as hypotheses concerning mediating mechanisms at the cognitive and affective levels. ClinicalTrials.gov ID: NCT05227612.
Get full access to this article
View all access options for this article.
References
1.
BogenschutzMP, ForcehimesAA, PommyJA, et al.Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. J Psychopharmacol, 2015; 29(3):289–299.
2.
BogenschutzMP, RossS, BhattS, et al.Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: A randomized clinical trial. JAMA Psychiatry, 2022; 79(10):953–962.
3.
JohnsonMW, Garcia-RomeuA, GriffithsRR. Long-term follow-up of psilocybin-facilitated smoking cessation. Am J Drug Alcohol Abuse, 2017; 43(1):55–60.
4.
MorenoFA, WiegandCB, TaitanoEK, et al.Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry, 2006; 67(11):0-.
5.
GrobCS, DanforthAL, ChopraGS, et al.Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry, 2011; 68(1):71–78.
6.
Carhart-HarrisRL, BolstridgeM, DayC, et al.Psilocybin with psychological support for treatment-resistant depression: Six-month follow-up. Psychopharmacology, 2018; 235(2):399–408.
7.
DavisAK, BarrettFS, MayDG, et al.Effects of psilocybin-assisted therapy on major depressive disorder: A randomized clinical trial. JAMA Psychiatry, 2021; 78(5):481–489.
8.
CuijpersP, CristeaIA, KaryotakiE, et al.How effective are cognitive behavior therapies for major depression and anxiety disorders? A meta-analytic update of the evidence. World Psychiatry, 2016; 15(3):245–258.
9.
FournierJC, DeRubeisRJ, HollonSD, et al.Antidepressant drug effects and depression severity: A patient-level meta-analysis. JAMA, 2010; 303(1):47–53.
10.
GukasyanN, DavisAK, BarrettFS, et al.Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. J Psychopharmacol, 2022; 36(2):151–158.
11.
GoodwinGM, AaronsonST, AlvarezO, et al.Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med, 2022; 387(18):1637–1648.
12.
VaidG, WalkerB. Psychedelic psychotherapy: Building wholeness through connection. Glob Adv Health Med, 2022; 11:2164957X221081113.
13.
JohnsonMW, RichardsWA, GriffithsRR. Human hallucinogen research: Guidelines for safety. J Psychopharmacol, 2008; 22(6):603–620.
14.
HollonSD, DeRubeisRJ, SheltonRC, et al.Prevention of relapse following cognitive therapy vs medications in moderate to severe depression. Arch Gen Psychiatry, 2005; 62(4):417–422.
15.
OttoMW, BirkJL, FitzgeraldHE, et al.Stage models for major depression: Cognitive behavior therapy, mechanistic treatment targets, and the prevention of stage transition. Clin Psychol Rev, 2022:102172.
16.
YadenDB, EarpD, GraziosiM, et al.Psychedelics and psychotherapy: Cognitive-behavioral approaches as default. Front Psychol, 2022; 13:1604.
17.
CameronSK, RodgersJ, DagnanD. The relationship between the therapeutic alliance and clinical outcomes in cognitive behaviour therapy for adults with depression: A meta-analytic review. Clin Psychol Psychother, 2018; 25(3):446–456.
18.
WeckF, RudariV, HillingC, et al.Relapses in recurrent depression 1 year after maintenance cognitive-behavioral therapy: The role of therapist adherence, competence, and the therapeutic alliance. Psychiatry Res, 2013; 210(1):140–145.
19.
GratzKL, WeissNH, TullMT. Examining emotion regulation as an outcome, mechanism, or target of psychological treatments. Curr Opin Psychol, 2015; 3:85–90.
20.
ClarkDA, BeckAT. Cognitive theory and therapy of anxiety and depression: Convergence with neurobiological findings. Trends Cogn Sci, 2010; 14(9):418–424.
21.
CuijpersP, KaryotakiE, CiharovaM, et al.The effects of psychotherapies for depression on response, remission, reliable change, and deterioration: A meta-analysis. Acta Psychiatr Scand, 2021; 144(3):288–299.
22.
KhanA, Fahl MarK, FaucettJ, et al.Has the rising placebo response impacted antidepressant clinical trial outcome? Data from the US Food and Drug Administration 1987–2013. World Psychiatry, 2017; 16(2):181–192.
23.
SimK, LauWK, SimJ, et al.Prevention of relapse and recurrence in adults with major depressive disorder: Systematic review and meta-analyses of controlled trials. Int J Neuropsychopharmacol, 2016; 19(2):pyv076.
24.
DossMK, PovažanM, RosenbergMD, et al.Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder. Transl Psychiatry, 2021; 11(1):1–10.
25.
KashdanTB, RottenbergJ. Psychological flexibility as a fundamental aspect of health. Clin Psychol Rev, 2010; 30(7):865–878.
26.
WolffM, MertensLJ, WalterM, et al.The acceptance/avoidance-promoting experiences questionnaire (APEQ): A theory-based approach to psychedelic drugs' effects on psychological flexibility. J Psychopharmacol, 2022; 36(3):387–408.
27.
DavisAK, BarrettFS, GriffithsRR. Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety. J Contextual Behav Sci, 2020; 15:39–45.
28.
MacLeanKA, JohnsonMW, GriffithsRR. Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. J Psychopharmacol, 2011; 25(11):1453–1461.
29.
KoK, KnightG, RuckerJJ, et al.Psychedelics, mystical experience, and therapeutic efficacy: A systematic review. Front Psychiatry, 2022; 13.
30.
BonsonKR.Hallucinogenic Drugs. In: eLS, Food and Drug Administration. John Wiley & Sons: Silver Springs, MD; 2012.
FirstMB, WilliamsJBW, KargRS, SpitzerRL: Structured Clinical Interview for DSM-5 Disorders, Clinician Version (SCID-5-CV). American Psychiatric Association: Arlington, VA; 2016.
33.
WeissmanMM, WickramaratneP, AdamsP, et al.Brief screening for family psychiatric history: The family history screen. Arch Gen Psychiatry, 2000; 57(7):675–682.
34.
American Psychiatric Association. Diagnostic and Statistical Manual Of Mental Disorders (DSM-5®). American Psychiatric Pub: Washington, DC; 2013.
35.
StrassmanRJ.Adverse reactions to psychedelic drugs. A review of the literature. J Nerv Ment Dis, 1984; 172(10):577–595.
36.
DittrichA.Psychological aspects of altered states of consciousness of the LSD type: Measurement of their basic dimensions and prediction of individual differences. In: (PletscherA, LadewigD. eds.) 50 Years of LSD: Current status and perspectives of hallucinogens. New York, NY: Parthenon; 1994. pp. 101–118.
37.
HaslerF, GrimbergU, BenzMA, et al.Acute psychological and physiological effects of psilocybin in healthy humans: A double-blind, placebo-controlled dose–effect study. Psychopharmacology, 2004; 172(2):145–156.
PosnerK, BrownGK, StanleyB, et al.The Columbia–suicide severity rating scale: Initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry, 2011; 168(12):1266–1277.
40.
BarlowDH, AllenLB, ChoateML. Toward a unified treatment for emotional disorders. Behav Ther, 2004; 35(2):205–230.
41.
BarlowDH, FarchioneTJ, BullisJR, et al.The unified protocol for transdiagnostic treatment of emotional disorders compared with diagnosis-specific protocols for anxiety disorders: A randomized clinical trial. JAMA Psychiatry, 2017; 74(9):875–884.
42.
CuijpersP, BerkingM, AnderssonG, et al.A meta-analysis of cognitive-behavioural therapy for adult depression, alone and in comparison with other treatments. Can J Psychiatry, 2013; 58(7):376–385.
43.
BourzatF, HunterK.Consciousness Medicine: Indigenous Wisdom, Entheogens, and Expanded States of Consciousness for Healing and Growth. North Atlantic Books: Berkeley, CA; 2019.
44.
WolffM, EvensR, MertensLJ, et al.Learning to let go: A cognitive-behavioral model of how psychedelic therapy promotes acceptance. Front Psychiatry, 2020; 11:5.
45.
HollonSD, CohenZD, SinglaDR, et al.Recent developments in the treatment of depression. Behav Ther, 2019; 50(2):257–269.
46.
KroenkeK, SpitzerRL, WilliamsJB. The PHQ-9: Validity of a brief depression severity measure. J Gen Intern Med, 2001; 16(9):606–613.
47.
GroveJR, PrapavessisH. Preliminary evidence for the reliability and validity of an abbreviated profile of mood states. Int J Sport Psychol, 1992; 23:93–109.
48.
American Psychiatric Association. DSM-IV-TR: Diagnostic and Statistical Manual of Mental Disorders, Text Revision. American Psychiatric Association: Washington, DC, USA; 2000.
49.
GuyW.ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Heath, Education, and Welfare Public Health Service Alcohol, Drug Abuse, and Mental Health Administration. 1976; pp. 217–222.
50.
FowlerD, FreemanD, SmithB, et al.The Brief Core Schema Scales (BCSS): Psychometric properties and associations with paranoia and grandiosity in non-clinical and psychosis samples. Psychol Med, 2006; 36(6):749–759.
51.
GratzKL, RoemerL. Multidimensional assessment of emotion regulation and dysregulation: Development, factor structure, and initial validation of the difficulties in emotion regulation scale. J Psychopathol Behav Assess, 2004; 26(1):41–54.
52.
JohnOP, SrivastavaS.The Big Five Trait taxonomy: History, measurement, and theoretical perspectives. In: Handbook of personality: Theory and research (PervinLA, JohnOP, eds.) Guilford Press; 1999; pp. 102–138.
53.
DittrichA.The standardized psychometric assessment of altered states of consciousness (ASCs) in humans. Pharmacopsychiatry, 1998; 31(S 2):80–84.
54.
YadenDB, KaufmanSB, HydeE, et al.The development of the Awe Experience Scale (AWE-S): A multifactorial measure for a complex emotion. J Positive Psychol, 2019; 14(4):474–488.
55.
BarrettFS, BradstreetMP, LeoutsakosJ-MS, et al.The challenging experience questionnaire: Characterization of challenging experiences with psilocybin mushrooms. J Psychopharmacol, 2016; 30(12):1279–1295.
56.
DavisAK, BarrettFS, SoS, et al.Development of the psychological insight questionnaire among a sample of people who have consumed psilocybin or LSD. J Psychopharmacol, 2021; 35(4):437–446.
57.
BarrettFS, JohnsonMW, GriffithsRR. Validation of the revised mystical experience questionnaire in experimental sessions with psilocybin. J Psychopharmacol, 2015; 29(11):1182–1190.
WilkinsonST, RheeTG, JoormannJ, et al.Cognitive behavioral therapy to sustain the antidepressant effects of ketamine in treatment-resistant depression: A randomized clinical trial. Psychother Psychosom, 2021; 90(5):318–327.
60.
WilkinsonST, WrightD, FasulaMK, et al.Cognitive behavior therapy may sustain antidepressant effects of intravenous ketamine in treatment-resistant depression. Psychother Psychosom, 2017; 86(3):162–167.
61.
JohnstonCB, ManginiM, GrobC, et al.The safety and efficacy of psychedelic-assisted therapies for older adults: Knowns and unknowns. Am J Geriatric Psychiatry, 2023; 31(1):44–53.
